Background-The Ca 2ϩ -activated chloride channel (CaCC) plays an important role in a variety of physiological functions.
T he Ca 2ϩ -activated chloride channel (CaCC) is ubiquitously expressed in almost all eukaryotic cell types. CaCC has been reported to be involved in the regulation of a variety of physiological activities, including epithelial fluid and electrolyte secretion, neuronal and cardiac excitability, vascular contractility, and oocyte fertilization. [1] [2] [3] [4] Although CaCC has been studied extensively for almost 3 decades, the functions of this channel are not fully understood. The major obstacle is the unknown molecular identity of the channel. Several candidates, including CLCA, ClC-3, and Tweety, have been proposed for CaCC, but these hypotheses were not supported by subsequent studies. [2] [3] [4] [5] [6] In 2002, bestrophins were proposed to be a CaCC in that heterogeneous expression of bestrophins could induce a Ca 2ϩ -sensitive Cl Ϫ current that shared some similarities with native Ca 2ϩ -activated chloride current (I Cl.Ca ). 1,3,4,6 -8 However, the conclusion that bestrophins are responsible for the CaCC remains controversial because inconsistent or even conflicting data has been reported. 9, 10 Clinical Perspective on p 707
The TMEM16/anoctamin (Ano) proteins are a family of transmembrane proteins that consists of 10 members (TMEM16A-H, TMEM16J, and TMEM16K). Most recently, these proteins were proposed to be the candidates for CaCC based on the observations that heterogeneous expression of TMEM16A/Ano1 or TMEM16B/Ano2 produced a Cl Ϫ cur-rent with the same characteristics as the native I Cl.Ca , including Ca 2ϩ and voltage dependence, outward rectification, and ion selectivity. [11] [12] [13] Accumulating evidence has suggested that TMEM16A is critical for the normal development of trachea, 14 transepithelial Cl Ϫ secretion, 15 and bradykinininduced inflammatory pain 16 and is associated with numerous types of cancers. [17] [18] [19] In the cardiovascular system, the expression of TMEM16A was initially identified in mouse portal vein by Sones et al. 20 Later, Davis et al 21 and Manoury et al 22 reported that TMEM16A is expressed in vascular smooth muscle cells of thoracic aorta, carotid artery, and pulmonary artery and was suggested to be responsible for the CaCC in these cells. However, the functions of TMEM16A in the vessels remain elusive.
Importantly, the activity of Cl Ϫ channels has been found to be cell cycle dependent in ascidian embryos and B lymphocytes, 23, 24 indicating that Cl Ϫ channels may be critical for cell cycle transition and cell proliferation. Previous studies from our laboratory and others have demonstrated that the volumeregulated chloride channel plays an important role in the regulation of cell cycle progression and cell proliferation in a variety of cell types. [25] [26] [27] [28] [29] [30] Moreover, our recent results revealed that the activity of volume-regulated chloride channel was increased in hypertensive rat basilar smooth muscle cells (BASMCs) and that the upregulation of volume-regulated chloride channel contributed to the hypertension-induced cerebrovascular remodeling by promoting BASMC proliferation. 31, 32 Although a recent study in Ehrlich-Lettre ascites cells suggested that CaCC may be also a critical regulator of cell proliferation, 33 whether CaCC is involved in cerebrovascular remodeling during hypertension is still a mystery.
In the present study, we examined the contributions of TMEM16A and bestrophin-3 to the CaCC in BASMCs and investigated whether the TMEM16A CaCC is involved in the regulation of cell proliferation and hypertensioninduced cerebrovascular remodeling and their underlying mechanisms.
Methods
An expanded Materials and Methods section is provided in the online-only Data Supplement.
Animal Model and Blood Pressure Measurement
All animal experimental procedures were performed in accordance with the policies of the Sun Yat-Sen University Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals of the National Institute of Health in China. Hypertensive rats (2-kidney, 2-clip [2k2c]) were operated on, and blood pressure was measured in conscious rats by tail-cuff plethysmography as described previously. 31, 32 
BASMC Isolation and Culture
Cell isolation and culture were carried out as previously described. 31, 32 Freshly isolated BASMCs were stored at 4°C and used for electrophysiological studies within 10 hours. Passages 8 through 12 of cultured BASMCs were used for cell proliferation assays.
siRNA Transfection
The siRNA duplexes against the rat TMEM16A gene or bestrophin-3 gene (Qiagen; Table I in the online-only Data Supplement) were transiently transfected with Hyperfect Transfection Reagent (Qiagen) according to the manufacturer's instructions. A negative siRNA (Qiagen) was used as negative control. Forty-eight hours later, the cells were used for cell proliferation assay, Western blot, or patch-clamp studies.
Plasmid Transfection
Phosphorylated enhanced green fluorescent protein-TMEM16A plasmid (kindly provided by Dr Lily Yeh Jan, University of California, San Francisco, CA) was transfected with Lipofectamine 2000 reagent (Invitrogen). Forty-eight hours later, the cells were used for cell proliferation assay, Western blot, or patch-clamp analysis.
Cell Proliferation Assay
Cell proliferation was assessed by cell counts and BrdU incorporation as we reported previously. 26, 31 Cell number was determined with a hemocytometer. BrdU incorporation was measured at 450 and 540 nm on an Elisa microplate reader (BIO-TEK Synergy HT).
Current Recording
Ca 2ϩ -activated Cl Ϫ current was recorded with an Axopatch 200B Amplifier (Axon Instrument, Foster City, CA) with a whole-cell patch clamp technique as previously described. 13, [33] [34] [35] The current was elicited with voltage steps from Ϫ100 to 100 mV in 20-mV increments for 250 milliseconds with an interval of 5 seconds from a holding potential of Ϫ50 mV and stored on a computer after digitalization at 5 kHz by Digidata1322A (Axon Instrument).
Reverse-Transcriptase Polymerase Chain Reaction
The expression of bestrophins (bestrophin-1, bestrophin-2 and bestrophin-3), members of TMEM16 family (TMEM16A-H, J, and K), and TMEM16A splice variants (a, b, c, and d) was assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) with a Onestep RT-PCR Kit (Qiagen). Synthesis of specific primers (Tables II-IV in the online-only Data Supplement) was performed by Shangon Biotech (Shanghai, China).
Statistical Analysis
All data are expressed as meanϮSEM. For Western blot, RT-PCR, and cell proliferation assays, n represents the number of independent experiments on different batches of cells or different rats. For patch-clamp studies, n represents the number of recorded cells from at least 4 different batches of cells or 5 different rats. The correlation analyses were determined by the Pearson correlation test. Statistical analysis was determined by an unpaired 2-tailed Student t test or 1-way ANOVA followed by the Bonferroni multiple comparison post hoc test with a 95% confidence interval. Differences in current density-voltage relationships were analyzed by 2-way ANOVA. Values of PϽ0.05 were considered significant.
Results

Ca 2؉ -Activated Cl ؊ Current in BASMCs
In the freshly isolated rat BASMCs, an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) evoked a [Ca 2ϩ ] idependent outward-rectifying current. The half-effective concentration of Ca 2ϩ (EC 50 ) to activate this current is 286.1Ϯ13.5 nmol/L (nϭ6 -9; Figure 1A ). The reversal potential (1.3Ϯ3.6 mV) of this current was near the equilibrium potential for Cl Ϫ (0 mV) in our experimental conditions. A reduction of the extracellular Cl Ϫ concentration (from 133 to 44 mmol/L) shifted the reversal potential to 20.8Ϯ2.3 mV, indicating that this current is carried mainly by Cl Ϫ ( Figure  1B ). Niflumic acid (100 mol/L) treatment significantly inhibited this current ( Figure 1C ). The characteristics of this current are similar to the I Cl.Ca recorded in the other types of vascular smooth muscle cells. 22, 37 In addition, we observed that both ATP, a purinoceptor agonist, and thapsigargin, a sarcoplasmic reticulum calcium pump inhibitor, could acti- 
TMEM16A But Not Bestrophin-3 Is Responsible for CaCC in Rat BASMCs
In rat BASMCs, bestrophin-3 is the most abundantly expressed isoform compared with bestrophin-1 and bestrophin-2 ( Figure IIA Recently, 2 members of the TMEM16 family, TMEM16A and TMEM16B, have been proposed to be the candidates for CaCC. [11] [12] [13] In BASMCs, RT-PCR analysis showed that the transcripts for TMEM16A, TMEM16C, TMEM16E through TMEM16H, TMEM16J, and TMEM16K are present; however, the transcripts for TMEM16B and TMEM16D were not detected ( Figure 2A ).
Because TMEM16B expression was not detected in BASMCs, we next investigated whether TMEM16A is responsible for CaCC in BASMCs. Consistent with previous studies, we found that TMEM16A overexpression induced a Ca 2ϩ -sensitive outward-rectifying current ( Figure 2B ). A reduction of extracellular Cl Ϫ concentration (from 133 to 44 mmol/L) shifted the reversal potential from Ϫ0.6Ϯ4.3 to 18.9Ϯ2.1 mV, indicating that this current is also carried mainly by Cl Ϫ . This Ca 2ϩ -sensitive Cl Ϫ current was remarkably inhibited by niflumic acid (100 mol/L; Figure III in the online-only Data Supplement). Moreover, we observed that knockdown of TMEM16A with anti-TMEM16A siRNA (40 nmol/L) decreased I Cl.Ca ( Figure 2C ). These results indicate that TMEM16A mediates I Cl.Ca in BASMCs.
To date, several TMEM16A splicing variants have been reported in various tissues, including vasculature. 11,20 -22,38 In BASMCs, RT-PCR amplified a single band using the primers specific for exons a and c, suggesting that these 2 exons are constitutively expressed in BASMCs. The primer specific for b amplified 3 bands in our results, indicating that the TMEM16A transcripts containing or lacking this exon are both expressed in BASMCs. As for exon d, only the short spliced band was amplified in BASMCs, indicating that the TMEM16A transcripts lack this exon ( Figure 2A ).
Alteration of I Cl.Ca in BASMCs From Hypertensive Rats
The 2k2c hypertensive rat model was established as we described previously. 31, 32 At 4, 8, and 12 weeks postoperatively, the mean values of blood pressure in the 2k2c group were significantly higher than those in shamoperated group (nϭ30 in each group; PϽ0.05, PϽ0.01 versus corresponding sham group; Figure IV in the onlineonly Data Supplement).
In BASMCs isolated from 2k2c hypertensive rats, ATPor thapsigargin-evoked I Cl.Ca was gradually decreased from 1 week after 2k2c operation ( Table V in hypertension and sham groups when [Ca 2ϩ ] i was clamped at 500 nmol/L. Our results showed that both the current amplitude and current densities of I Cl.Ca were remarkably reduced in hypertensive rat BASMCs from 1 week after surgery and that the I Cl.Ca was negatively correlated with blood pressure ( Figure 3A 
I Cl.Ca Is Negatively Correlated With Hypertension-Induced Cerebrovascular Remodeling
In agreement with our previous studies, 31, 32 cerebral vessels exhibited inward remodeling in 2k2c hypertensive rats. In basilar arteries, the wall and lumen diameter decreased and the wall-to-lumen area ratio and mean values of medial cross-sectional area increased in the hypertension group from 4 weeks postoperatively compared with those in the corresponding sham groups ( Figure  4A-4D ). More interestingly, we found that I Cl.Ca was negatively correlated with the medial cross-sectional area of basilar artery during hypertension ( Figure 4E ), suggesting that the decrease of I Cl.Ca may be involved in hypertension-induced cerebrovascular remodeling.
Downregulation of TMEM16A in the Basilar Artery From Hypertensive Rats
Because TMEM16A is a critical component of the CaCC in BASMCs, we next investigated whether the reduced expression of TMEM16A attributed to the decrease of I Cl.Ca during hypertension. Western blot results showed that TMEM16A expression in basilar artery did not change in the sham group during the time course (0 -12 weeks) we studied. However, its expression was gradually decreased in 2k2c hypertensive rats from 4 weeks after operation. At 4, 8, and 12 weeks after surgery, TMEM16 expression was reduced by 17%, 43%, and 74%, respectively (nϭ5; PϽ0.05, PϽ0.01 versus sham; Figure 5 ). Our results indicate that the decreased expression of TMEM16A underlies, at least in part, the downregulation of I Cl.Ca in BASMCs during hypertension.
Regulation of I Cl.Ca by CaMKII in BASMCs From 2k2c Hypertensive Rats
It is noteworthy, however, that the decrease of I Cl.Ca preceded the downregulation of TMEM16A expression, indicating that a reduction of TMEM16A expression is not the only mechanism attenuating the activity of CaCC during hypertension. Therefore, we next examined the effect of CaMKII on I Cl.Ca because previous studies have demonstrated that CaMKII is a negative regulator of CaCC in rabbit pulmonary and coronary arterial smooth muscle cells. 34 In freshly isolated rat BASMCs, KN-93, a specific Figure  6A ). A similar effect of KN-93 on TMEM16A-mediated Cl Ϫ current was also observed in TMEM16Aoverexpressing BASMCs (Figure 6B ), suggesting the involvement of CaMKII in regulating the activity of TMEM16A channel. Moreover, we found that KN-93 induced a more dramatic increase in I Cl.Ca in the hypertensive groups than in the corresponding sham groups ( Figure  6C ). Furthermore, the activity of CaMKII in basilar artery began to increase from 1 week after surgery and its activity was elevated gradually along with the development of hypertension ( Figure 6D and 6E) . These results suggest that the elevated CaMKII activity also contributes to the downregulation of I Cl.Ca during hypertension.
Effect of TMEM16A on Angiotensin II-Induced BASMC Proliferation
In cultured BASMCs, angiotensin II (AngII; 0.5 mol/L) treated for 48 hours significantly decreased TMEM16A expression (nϭ6; PϽ0.01 versus control; Figure 7A ). This prompted us to further examine whether the downregulation of TMEM16A exerts a functional role in the regulation of AngII-induced cell proliferation because vascular smooth muscle cell proliferation plays an important role in hypertension-induced cerebrovascular remodeling. Our results demonstrated that knockdown of TMEM16A with anti-TMEM16A siRNA (40 nmol/L) promoted AngIIinduced BASMC proliferation (nϭ6; PϽ0.05 versus control; PϽ0.05 versus AngII-only group; Figure 7B and 7F and Figure VIA in the online-only Data Supplement). In contrast, overexpression of TMEM16A inhibited AngII-induced . Western blot showed that TMEM16A expression in basilar arteries from hypertensive rat was decreased compared with that in the corresponding sham rats from 4 weeks after operation (right; nϭ5 in each group; *PϽ0.05, **PϽ0.01 vs control). However, TMEM16A expression did not change in basilar arteries from sham rats in the time course we studied (left; nϭ5 from 12 rats in each group). BASMC proliferation (nϭ6; PϽ0.05 versus control; PϽ0.05 versus AngII-only group; Figure 7C and Figure VIB in the online-only Data Supplement). The data suggests that downregulation of TMEM16A is involved in AngII-induced cell proliferation.
Effect of TMEM16A on Cell Cycle in AngII-Stimulated BASMCs
As shown in Figure 7 , AngII (0.5 mol/L) promoted the cell cycle transition from the G0/G1 phase to the S phase in BASMCs. AngII decreased the percentage of cells in the G0/G1 phase and increased the percentage of cells in the S phase. Knockdown of TMEM16A increased the effect of AngII on cell cycle transition, which decreased the percentage of cells in the G0/G1 phase from 72.3Ϯ4.7% to 59.4Ϯ3.1% and enhanced the percentage of cells in the S phase from 23.3Ϯ1.5% to 36.1Ϯ3.3% (nϭ6; PϽ0.05 versus control; PϽ0.05 versus AngII-only group; Figure 7D ). In contrast, overexpression of TMEM16A inhibited AngIIinduced cell cycle progression with a decrease in the cell population in the S phase from 25.7Ϯ1.7% to 14.2Ϯ1.3% and an increase in the cell population in the G0/G1 phase from 72.9Ϯ1.2% to 83.3Ϯ2.3% (nϭ6; PϽ0.05 versus control; PϽ0.05 versus AngII-only group; Figure 7E ). Our data indicates that downregulation of TMEM16A facilitates cell entrance from the G0/G1 phase to the S phase in BASMCs and thus promotes cell proliferation.
Effect of TMEM16A on Cell Cycle Regulators
Cell cycle transition is a tightly controlled event that is positively regulated by cyclins and cyclin-dependent kinases and negatively regulated by cyclin-dependent kinase inhibitors. To explore the molecular mechanism by which TMEM16A affects G1/S transition, we analyzed the proteins regulating cell cycle progression in these cell phases, including cyclin-dependent kinase-2, cyclin D1, cyclin E, p21 CIP , and p27 KIP . We found that knockdown of TMEM16A increased and overexpression of TMEM16A decreased AngII-induced expression of cyclin D1 and cyclin E (nϭ6; PϽ0.05 versus control group; PϽ0.05 versus AngII-treated group; Figure 8A and 8B). However, knockdown or overexpression of TMEM16A had no effect on cyclin-dependent kinase-2, p21 CIP , and p27 KIP expression in BASMCs ( Figure 8C and 8D ).
Discussion
Currently, the physiological functions of CaCC are not fully understood because of the lack of specific channel blockers and the uncertainty about its molecular identity. In 2002, Sun et al 6 proposed that bestrophins may be the molecular candidates for CaCC based on the observation that hBest1 overexpression in human embryonic kidney 293 cells induced a Ca 2ϩ -sensitive Cl Ϫ current. This hypothesis was further supported by several subsequent studies. 7, 8, 39, 40 However, skepticism remains because Ca 2ϩ -sensitive Cl Ϫ current still exists in mBest1 or hBest2 knockout mice. 9, 10 In vascular smooth muscle cells, 2 types of I Cl.Ca , "classic" I Cl.Ca and cGMP-dependent I Cl.Ca , have been found. Interestingly, a recent work demonstrated that bestrophin-3 is responsible for cGMP-dependent I Cl.Ca but not classic I Cl.Ca in vascular smooth muscle cells. 41 In the present study, we found that bestrophin-3 is the most abundantly expressed isoform in rat basilar artery. However, knockdown of bestrophin 3 with siRNA had no effect on I Cl.Ca , indicating that bestrophin-3 contributes little to the CaCC in BASMCs.
Several recent lines of evidence support that TMEM16A (Ano1) and TMEM16B (Ano2), 2 members of anoctamin family, encode CaCC in various cell types. 11, 13, 15, 16, 22, 42, 43 Most recently, the expression profile of TMEM16 family members and their contributions to the CaCC in vascular smooth muscle cells have been examined in several types of blood vessels. For example, Sones et al 20 detected the expression of TMEM16A in murine portal vein. Davis et al 21 observed the expression of TMEM16A and TMEM16B in murine conduit artery. Manoury et al 22 identified the expression of TMEM16A-B, TMEM16D-F, and TMEM16K in cultured pulmonary arterial smooth muscle cells. Most recently, a study published while we were preparing our revision reported that only the transcript for TMEM16A is expressed in cerebral arterial smooth muscle cells. 38 Here, in basilar artery, we found that TMEM16A, TMEM16C, TMEM16E, TMEM16F, and TMEM16K are expressed at high levels, whereas TMEM16B and TMEM16D are not detected. The differences in the expression profile of the TMEM16 family in our study compared with previous studies may be due to the different species and the size and types of vessels studied. Because TMEM16B was not detected in BASMCs, we next examined the relationship between TMEM16A and CaCC in BASMCs. We found that heterogeneous expression of TMEM16A could induce a Ca 2ϩsensitive Cl Ϫ current with properties similar to the native I Cl.Ca in BASMCs. Moreover, we found that TMEM16A is endogenously expressed in rat BASMCs. Knockdown of TMEM16A with siRNA remarkably attenuated I Cl.Ca in BASMCs. The data suggests that TMEM16A is responsible for the CaCC in BASMCs.
Cerebrovascular remodeling has been thought to be an important determinant of the increased risk of stroke that accompanies chronic hypertension. 44, 45 Alteration of several kinds of ion channels, including the Ca 2ϩ channel, K ϩ channel, and volume-regulated Cl Ϫ channel, has been suggested to play a critical role in hypertension-induced cerebrovascular remodeling. 46 -48 The CaCC has been reported to be Growth-arrested BASMCs were pretreated with 40 nmol/L anti-TMEM16A siRNA; 48 hours later, 0.5 mol/L AngII was added to the culture medium for another 48 hours, and the cells were then collected for BrdU assay (nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngIItreated group). C, Overexpression of TMEM16A inhibited AngII-induced BASMC proliferation. Growth-arrested BASMCs were transiently transfected with phosphorylated enhanced green fluorescent protein (pEGFP)-TMEM16A for 48 hours; after that, 0.5 mol/L AngII was added to the culture medium for another 48 hours, and the cells were then collected for BrdU assay (nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngII-treated group). D, Downregulation of TMEM16A accelerated AngII-induced G1/S transition in BASMCs. Growtharrested BASMCs were pretreated with 40 nmol/L anti-TMEM16A siRNA; 48 hours later, 0.5 mol/L AngII was added to the culture medium for another 48 hours; then, the cells were collected for flow cytometric analysis (nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngIItreated group). E, Overexpression of TMEM16A inhibited AngII-induced G1/S transition in BASMCs. Growth-arrested BASMCs were transiently transfected with pEGFP-TMEM16A for 48 hours; after that, 0.5 mol/L AngII was added to the culture medium for another 48 hours, and then the cells were collected for flow cytometric analysis (nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngII-treated group). Neg indicates negative siRNA; Re, Hyperfect transfection reagent.
involved in the regulation of cerebrovascular contraction [2] [3] [4] ; however, the possible functions of this channel in cerebrovascular remodeling are not fully appreciated. Our results demonstrated that in BASMCs isolated from 2k2c hypertensive rats, both I Cl.Ca and TMEM16A expression were reduced. Moreover, the activity of I Cl.Ca negatively correlated with blood pressure and the medial cross-sectional area of basilar artery during hypertension development. These findings indicate that downregulation of CaCC may be involved in cerebrovascular remodeling during the development of hypertension.
It is noteworthy that the downregulation of TMEM16A expression cannot fully explain the decreased activity of CaCC in 2k2c hypertensive rats because I Cl.Ca began to drop at 1 week after operation but TMEM16A reduction was observed until 4 weeks after surgery. To further determine the mechanisms underlying the downregulation of CaCC during hypertension, we investigated the effect of CaMKII on I Cl.Ca in BASMCs because CaMKII has been proposed to be a negative regulator of CaCC in rabbit coronary myocytes. 34 Consistent with this study, we found that the native I Cl.Ca and TMEM16A-mediated currents were negatively regulated by CaMKII. Addition of KN-93, a CaMKII inhibitor, potentiated the native I Cl.Ca in BSMCs and TMEM16A-mediated Cl Ϫ currents. Moreover, we found that the percentage increases of I Cl.Ca by KN-93 were substantially elevated and accompanied by blood pressure increases, suggesting that CaMKII activity may be upregulated in hypertension. Indeed, the activity of CaMKII in basilar artery was augmented from 1 week after operation. Our findings were in agreement with previous work demonstrating that CaMKII activity was upregulated in AngII-induced vascular hyperplasia and hypertension. 34, 49 Together, our data demonstrates that the activity of CaCC in BASMCs was reduced in hypertension. Both the increased activity of CaMKII and decreased expression of TMEM16A contributed to the hypertension-induced downregulation of CaCC.
Abnormal vascular smooth muscle cell proliferation is a critical contributor to hypertension-induced vascular remodeling. 31, 44 Recent growing evidence has supported that Cl Ϫ channels play an important role in regulating cell proliferation and cell cycle transition in a variety of cell types. 23,24,26 -30 In Ehrlich-Lettre ascites cells, a previous study demonstrated that the activity of CaCC was cell cycle dependent and that I Cl.Ca was decreased when the cell entered the S phase from the quiescent G 0 phase, 33 suggesting that CaCC may be a critical cell cycle regulator and may play an important role in cell proliferation. In the present study, we found that AngII treatment decreased TMEM16A expression in rat BASMCs. Knockdown of TMEM16A facilitated the AngII-induced cell cycle transition from the G0/G1 phase to the S phase and promoted cell proliferation. In contrast, Figure 8 . Effects of TMEM16A on cell cycle regulatory proteins. A, Knockdown of TMEM16A with anti-TMEM16A siRNA significantly increased angiotensin II (AngII)-induced cyclin D1 and cyclin E expression in basilar smooth muscle cells (BASMCs; nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngII-treated group). B, Representative Western blot images and densitometric analysis showed that TMEM16A cDNA transfection significantly decreased AngII-induced cyclin D1 and cyclin E expression in BASMCs (nϭ6; *PϽ0.05 vs control; #PϽ0.05 vs AngII-treated group). C and D, Knockdown or overexpression of TMEM16A did not influence the protein expression of cyclin-dependent kinase-2, p21 CIP , and p27 KIP . Representative blots from 6 different experiments are shown. Neg indicates negative siRNA; Re, Hyperfect transfection reagent. overexpression of TMEM16A arrested the cell cycle at the G0/G1 phase and inhibited AngII-induced cell proliferation. Moreover, our results revealed that knockdown of TMEM16A further increased and overexpression of TMEM16A decreased AngII-induced upregulation of cyclin D1 and cyclin E in BASMCs. These observations indicated that TMEM16A-mediated CaCC is an effective cell proliferation inhibitor by preventing cell cycle transition from the G0/G1 phase to the S phase via inhibition of cyclin D1 and cyclin E expression. Downregulation of TMEM16Amediated CaCC is involved in AngII-induced BASMC proliferation. Our results seems to be contradictory to previous studies which reported that TMEM16A was upregulated in several cancers, including oral cancer and gastrointestinal stromal tumors, before it was identified as CaCC. [17] [18] [19] Of note, however, is that the exact functions of TMEM16A upregulation in cancer cells remain enigmatic.
Conclusions
Our present study provides evidence that TMEM16A but not bestrophin-3 is responsible for the CaCC in BASMCs. TMEM16A-mediated CaCC is a negative regulator of cell proliferation by arresting the cell cycle at the G0/G1 phase through a reduction of cyclin D1 and cyclin E expression. During hypertension, the activity of CaCC in BASMCs is decreased as a result of upregulation of CaMKII activity and downregulation of TMEM16A expression. These results suggest that a reduction of CaCC in hypertension may play an important role in the regulation of vascular smooth muscle cell proliferation and thus contribute to hypertension-induced cerebrovascular remodeling, indicating that modification of the activity of CaCC may be a novel therapeutic approach for hypertension-associated cardiovascular diseases such as stroke.
